AB SCIEX and Indigo BioSystems Team Up to Accelerate Adoption of Next-generation Mass Spectrometry for Clinical Research, Forensic Toxicology and Clinical Trials

FRAMINGHAM, Mass. & INDIANAPOLIS--(BUSINESS WIRE)--AB SCIEX and Indigo BioSystems today announced an agreement to jointly market mass spectrometry solutions that streamline data acquisition and automate data review to ensure high quality results in clinical research and forensic toxicology as well as pre-clinical and clinical trials of new drugs. These joint solutions are expected to simplify and accelerate the use of new-generation mass spectrometry technologies, which will be exhibited at the AB SCIEX and Indigo BioSystems booths this week at the Mass Spectrometry Applications to the Clinical Lab (MSACL) conference in San Diego.

MORE ON THIS TOPIC